GlassScriptPhysician profile
Jordan Wester
NPI 1174088967
$9,621.17
in general payments reported to CMS, 2019-2025
30 companies · $2,522 in 2025
The $2,522 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,454 · 2023: $1,788 · 2024: $2,575 · 2025: $2,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,885.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,887.16 | 2021-2025 | Evenity, Enbrel, Krystexxa |
| Abbvie INC. | $1,290.93 | 2021-2025 | |
| Ucb, INC. | $1,048.32 | 2022-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $760.31 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $600.78 | 2021-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $554.82 | 2021-2025 | |
| Horizon Therapeutics Plc | $550.78 | 2021-2022 | |
| Glaxosmithkline, LLC. | $522.50 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $429.83 | 2022-2025 | Acthar |
| Lilly USA, LLC | $372.12 | 2021-2025 | Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.87 | 2021-2025 | Ofev |
| Genzyme Corporation | $210.00 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $143.65 | 2021-2024 | Lupkynis |
| Pfizer INC. | $102.68 | 2022-2025 | |
| Tersera Therapeutics LLC | $98.71 | 2022-2024 | Quzyttir |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $87.77 | 2024-2025 | Strensiq, Ultomiris |
| Genentech USA, INC. | $85.45 | 2023-2025 | Actemra |
| Fresenius Kabi USA, LLC | $82.53 | 2023-2024 | Idacio |
| Bioventus LLC | $70.49 | 2024-2025 | Supartz Fx Sodium Hyaluronate, Durolane, Xcell |
| Ferring Pharmaceuticals INC. | $57.50 | 2025 | Euflexxa |
| Scilex Pharmaceuticals INC. | $57.43 | 2024 | |
| Ani Pharmaceuticals, INC. | $57.15 | 2024-2025 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $55.32 | 2024 | Octagam Immune Globulin (Human) |
| Organon LLC | $52.05 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.85 | 2024-2025 | Orencia |
| Radius Health, INC. | $25.93 | 2025 | Tymlos |
| Kiniksa Pharmaceuticals International, Plc | $24.66 | 2024 | Arcalyst |
| Cgg Medical INC | $24.31 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $22.29 | 2023 | Zilretta, Iovera |
| Sobi, INC | $17.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Wester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.